As a new foreign trade service provider driven by technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original DMSO products from multiple well-known brands. Having engaged in the DMSO foreign trade market for over a decade, HiSiaddi has sorted out global supply and demand market conditions for your reference.
For inquiries about DMSO supply-demand market trends or product consultation, please contact HiSiaddi customer service or visit our official website www.hisiaddi.com.
1. Dimethyl Sulfide (DMS): Accounts for 60–68% of total DMSO production cost; synthesized from methanol and hydrogen sulfide, relying on coal chemical and sulfur chemical industrial chains. Crude oil and natural gas prices directly transmit methanol cost fluctuations; a 10% DMS price swing drives a 6–7% fluctuation in finished DMSO prices.
2. Oxidant (Hydrogen Peroxide / Oxygen): Accounts for 12–18% of total cost; nitric acid oxidation processes are gradually restricted by environmental policies, with green continuous hydrogen peroxide oxidation becoming the mainstream technology.
3. High-Purity Distillation Solvents, Molecular Sieves & Filter Consumables: An additional 8–12% purification processing cost for high-end pharmaceutical/electronic grades.
Supply Pattern: Domestic manufacturers including Wanhua, Luxi and Hualu Hengsheng achieve integrated supporting capacity for methanol, hydrogen sulfide and DMS with self-sufficiency of 70–90%, delivering 15–20% lower comprehensive production costs than manufacturers purchasing external DMS. Overseas manufacturers Merck and BASF rely on outsourced raw materials with significantly higher production costs than Chinese integrated leaders.
Global total capacity of 165,000 tons/year in 2025; domestic manufacturers Wanhua + Yaxing + Zhongdan account for 58% of capacity, overseas Merck+BASF+JSR account for 36%. Single continuous distillation clean production line fixed asset investment exceeds RMB 52 million, single batch purification cycle 4–6 days, capacity expansion cycle 14 months. Exclusively supplied to global GLP-1 peptide APIs, advanced wafers and high-end lithium battery tracks with stable full-capacity utilization rate of 92%.
China’s total capacity of 335,000 tons/year (2025), dominated by small & medium fine chemical enterprises; low equipment investment, 6-month capacity expansion cycle. Supplies global CRO laboratories and bulk industrial synthesis with capacity utilization rate of 65–72%, oversupply and price competition squeezing gross profit margins continuously.
Small-scale workshops subject to continuous environmental elimination; no export qualifications for pharmaceutical/electronic applications.
1. Pharmaceutical Sector (GLP-1 Peptides, Topical Formulations, Cell Cryopreservation): 56.2% (Core High-Growth Track). Global weight-loss and diabetes peptide drugs undergo continuous capacity expansion; sterile pharmacopoeia DMSO is irreplaceable with an annual growth rate of 9.2%.
2. Electronic Semiconductor / High-End Lithium Batteries: 17.8% (Fastest-Growing Track CAGR12.4%). Advanced process wafers, photoresist stripping and lithium battery slurry drive explosive demand for SEMI ultra-high-purity electronic grade DMSO.
3. Clinical CRO, University Laboratory ACS Reagents: 16.5%
4. Bulk Industrial Organic Synthesis, Coatings, Pesticide Additives: 9.5% (Stable Low-Growth Segment)
2025 Global DMSO Market Size: USD 266 million; 2026: USD 286 million; 2026–2032 CAGR:7.48%, 2032 projected market size: USD 440 million.
Regional Breakdown (2025):
· Asia-Pacific: USD 101 million (38%, concentrated Chinese peptide and semiconductor industries)
· Europe: USD 106 million (40%, Novo Nordisk and European CDMO clusters)
· North America: USD 48 million (18%)
· Others: USD 11 million (4%)
China is the world’s largest DMSO producer and exporter; domestic consumption rose 21.1% year-on-year in 2025, far exceeding the global average growth rate.
1. Wanhua Chemical, Shandong Yaxing Chemical: 36.1% global market share, domestic industry leaders with world’s largest continuous multi-stage distillation dual pharmaceutical & electronic grade production capacity, integrated coal chemical upstream & downstream supply chain with prominent cost advantages; rising export share to European peptide CDMOs year-on-year.
2. Merck, BASF: 22.0% global market share, overseas high-end brands, fixed suppliers for multinational pharmaceutical and native semiconductor manufacturers with significant brand premium.
3. Jiangsu Zhongdan, Zhejiang Xinnong, JSR, Evonik: Combined 19.7% market share, specialized in segmented tracks; Zhongdan focuses on pharmaceutical grade, JSR specializes in electronic semiconductor grade.
4. Domestic small & medium single-tower batch distillation manufacturers: Combined 22.2% market share, only supply industrial and low-end laboratory use with no stable high-purity pharmacopoeia/electronic grade capacity.
Core Market Shift: Domestic continuous multi-stage distillation high-purity DMSO captured over 58% global market share in 2025, completely breaking the high-end monopoly of European, American and Japanese manufacturers. Accelerated localization of domestic pharmaceutical and semiconductor industrial chains drove a 9.7% year-on-year decline in imports of pharmacopoeia/electronic grade DMSO in 2024, with domestic substitution trend accelerating continuously.
1. East China (Shandong, Jiangsu, Zhejiang): Global core production cluster with total capacity of 500,000 tons (2025), accounting for 92% of national capacity. Shandong benefits from integrated coal chemical chains with the lowest domestic production cost (RMB 8,200–8,600/ton); Jiangsu and Zhejiang face higher energy costs (RMB 8,800–10,100/ton).
2. Europe & America (Germany, United States): Only retain small-batch high-end pharmacopoeia and electronic grade production lines; fully rely on China for industrial grade imports.
3. Japan, South Korea, Southeast Asia: No standardized continuous multi-stage distillation production lines; all high-purity DMSO imported from China, Europe or the US.
· Continuous multi-stage distillation pharmacopoeia/electronic high-purity capacity: 92% (tight supply balance sustained by GLP-1 and semiconductor capacity expansion; integrated leaders hold strong pricing power)
· Single-tower batch distillation reagent/industrial grade capacity: 66.8% (oversupply, vicious price competition with compressed gross profit margins; unable to meet strict FDA/SEMI impurity control thresholds for high-end applications)
Structural Differentiation Conclusion: GC≥99.9% multi-stage distillation high-purity DMSO remains in short supply; low-end batch distillation industrial/reagent grade suffers chronic overcapacity and price competition, and cannot be applied to injectable APIs or advanced semiconductor manufacturing.
Continuous capacity doubling for semaglutide and tirzepatide worldwide. DMSO serves as the only low-toxicity ICH Class 3 solvent for side-chain conjugation, solid-phase peptide synthesis and sterile cell cryopreservation. DMF/NMP face continuous EU usage restrictions due to reproductive toxicity, pushing full pharmaceutical industry shift to DMSO; rigid demand for pharmacopoeia high-purity DMSO with no mature alternative technology.
2nm/3nm advanced wafers, MiniLED packaging & testing and high-nickel lithium battery slurry production require SEMI ultra-high-purity DMSO for photoresist stripping and circuit cleaning. Domestic procurement share of domestic manufacturers SMIC, JCET and Tongfu Microelectronics rises annually, driving over 12% annual growth in electronic grade DMSO demand.
Wanhua and Yaxing Chemical’s multi-stage distillation impurity control, full REACH/FDA/SEMI compliance documentation fully benchmark Merck and JSR. European and American peptide CDMOs and packaging factories massively switch to domestic DMSO, leading to shrinking import demand for high-purity DMSO.
European and American pharmaceutical companies outsource solid-phase peptide and ADC intermediate production to Chinese CDMOs, driving over 20% annual growth in domestic high-purity DMSO exports.
1. Cyclical sharp price hikes of upstream coal chemical raw materials methanol and DMS compress procurement budgets for peptide and semiconductor manufacturers, leading to short-term inventory reduction.
2. New alternative solvents for laboratory small-molecule synthesis only apply to niche substrates, unable to replace DMSO’s core functions in aqueous bioconjugation and wafer cleaning; only divert minor low-end R&D demand.
3. Periodic decline in global pharmaceutical capital expenditure suppresses ACS reagent grade demand amid short-term volatility in early clinical CRO orders.
1. Total Exports: 216,000 tons, export value RMB 1.43 billion, +20.8% YoY; export structure: 42% pharmacopoeia/electronic high-purity grade, 58% industrial/reagent grade; key export destinations: Europe, Southeast Asia, North America
2. Total Imports: 14,200 tons, import value RMB 410 million, -9.7% YoY; all imports are Merck/JSR overseas pharmacopoeia/ultra-high-purity electronic grade for foreign-owned pharmaceutical and wafer manufacturers in China
3. HS Code: 29309000 (Other organosulfur compounds); Most-Favored-Nation import tariff 6.5%, import VAT 13%; export VAT rebate 13%; tariff reduction available under RCEP free trade agreements with Japan and South Korea.
Trade Trend: Rapid export growth and shrinking high-end imports. Import volume of pharmacopoeia/electronic grade DMSO is projected to drop below 6,000 tons after new domestic high-purity distillation capacity enters full production in 2027.
· Domestic Multi-Stage Distillation USP Pharmacopoeia Sterile Grade: RMB 380,000–450,000/ton (FOB Shanghai); Imported Merck Pharmacopoeia CIF tax-inclusive: RMB 900,000–1,200,000/ton, over 130% price premium
· Domestic SEMI Ultra-High-Purity Electronic Grade: RMB 360,000–430,000/ton; Imported JSR/Evonik: RMB 580,000–700,000/ton
· Domestic ACS Batch Distillation Reagent Grade: RMB 18,000–24,000/ton
· National Standard Industrial Grade (≥99.5%): RMB 8,500–12,000/ton
· DMS Intermediate: 64%
· Hydrogen Peroxide Oxidant: 16%
· Multi-Stage Negative Pressure Distillation + Sterile Filtration Energy & Consumables: 9%
· Class 10,000 Cleanroom Labor + Nitrogen-Sealed Constant-Temperature Storage: 6%
· Full REACH/DMF/ICH Testing & Audit Compliance Expenses: 5% A 10% DMS price swing drives a corresponding 6.2–7% fluctuation in finished DMSO prices.
1. Multi-Stage Distillation Pharmacopoeia/Electronic High-Purity Grade: High purification process barriers, tight supply balance sustained by GLP-1 and semiconductor rigid demand; integrated leaders maintain stable pricing with no vicious low-price competition.
2. Batch Distillation Reagent/Industrial Grade: Domestic overcapacity; small manufacturers relax impurity control and simplify moisture-proof packaging to compete on low prices, continuously squeezing industry gross profit margins.
1.
Process Barrier of Continuous Multi-Stage Negative Pressure Distillation Deep Impurity Removal Closed-loop integrated processes including low-temperature sealed continuous oxidation, four-step gradient distillation for sulfur impurity separation, molecular sieve deep dehydration and sterile ultrafiltration. Small and medium enterprises lack specialized equipment and peptide/semiconductor impurity control know-how, unable to stably produce 99.9% purity DMSO with dimethyl sulfone ≤0.03%. Impurity control directly determines whether downstream API and wafer yield meet FDA/SEMI standards.
2.
3.
Global Multi-Region Pharmaceutical & Electronic Compliance Certification Barrier Full REACH registration, CPNP notification, FDA TSCA, API DMF, SEMI semiconductor certification and cGMP cleanroom audit investment exceed RMB 10 million with a 2–3 year approval cycle. Original supply chain access verification for Novo Nordisk and TSMC takes over 1 year; new market entrants struggle to penetrate high-volume commercial supply chains.
4.
5.
Upstream DMS Full Industrial Chain Integration Barrier Self-supported methanol, hydrogen sulfide and DMS synthesis facilities reduce raw material costs by 15–20%. Manufacturers relying on outsourced DMS face cost pressure with no price competitiveness in the high-end market.
6.
7.
Heavy Asset Capacity Barrier Single multi-stage distillation clean production line fixed asset investment exceeds RMB 52 million; long purification cycle and 14-month capacity expansion cycle restrict rapid new high-purity capacity release to ease tight supply balance in the short term.
8.
1. Domestic Wanhua, Yaxing and Zhongdan plan to add combined 72,000 tons of continuous multi-stage distillation pharmacopoeia/electronic high-purity capacity, concentrated for commissioning in 2026–2027.
2. Merck, BASF and JSR have no large-scale high-purity capacity expansion plans; limited incremental overseas high-end supply.
3. Small manufacturers without compliant distillation equipment face continuous environmental elimination; low-grade crude capacity shrinks year-on-year. Projected global total multi-stage distillation 99.9% high-purity capacity in 2032: 248,000 tons, with domestic Chinese capacity accounting for over 68%.
1. Continuous capacity doubling of global GLP-1 peptide and ADC APIs with 100% penetration of pharmacopoeia high-purity DMSO.
2. Capacity expansion of advanced process wafers and high-nickel lithium batteries driving 12% CAGR for SEMI electronic grade DMSO.
3. Global peptide CDMO transfer to China sustains over 20% annual growth in high-purity DMSO exports. Projected global total DMSO demand in 2032: 546,000 tons, CAGR 7.48%.
2026–2028: Tight supply balance maintained for 99.9% multi-stage distillation pharmacopoeia/electronic high-purity grades; upstream DMS raw material price fluctuations directly impact procurement costs. Post-2029: Supply-demand balance for high-purity grades gradually eases after full commissioning of new domestic high-purity capacity. Batch distillation reagent/industrial grade will remain chronically oversaturated with unchanged low-price competition landscape.
1. Cyclical sharp price hikes of upstream coal chemical methanol and DMS raise overall procurement costs for pharmacopoeia/electronic high-purity DMSO.
2. Continuous tightening of EU REACH, FDA ICH impurity and SEMI semiconductor regulatory standards accelerates elimination of small manufacturers without multi-stage distillation and full compliance documentation.
3. Short-term volatility in global GLP-1 drug sales expectations slows capacity expansion by multinational pharmaceutical companies, temporarily suppressing demand for pharmacopoeia high-purity DMSO.
4. Extremely high hygroscopicity of DMSO leads to mass degradation and scrappage losses if full-process nitrogen-sealed cold-chain storage & transport controls are improperly managed.
5. Changes in import/export tariffs for chemical intermediates and pharmaceutical supply chain verification policies impact cross-border procurement and export order profitability.
Green hydrogen peroxide oxidation process transformation and environmental production restrictions may temporarily curtail high-end distillation capacity supply and push up spot prices.
+86-13120989737 
info@hisiaddi.com 
English
